المؤلفون: Sue M; Discovery Research Laboratories II, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Tsubaki T; Modality Research Laboratories III, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Ishimoto Y; Translational Science Department I, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Hayashi S; Discovery Research Laboratories II, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Ishida S; Discovery Research Laboratories II, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Otsuka T; Research Innovation Planning Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Isumi Y; Discovery Research Laboratories II, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Kawase Y; Discovery Research Laboratories V, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Yamaguchi J; Discovery Research Laboratories I, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Nakada T; Modality Research Laboratories I, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Ishiguro J; Discovery Research Laboratories V, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Nakamura K; Modality Research Laboratories II, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Kawaida R; Discovery Research Laboratories V, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Ohtsuka T; Discovery Research Laboratories V, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Wada T; Discovery Research Laboratories II, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Agatsuma T; R&D Division, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Kawasaki N; Discovery Research Laboratories II, Daiichi Sankyo Co., Ltd., Tokyo, Japan.

المصدر: PloS one [PLoS One] 2024 Jun 06; Vol. 19 (6), pp. e0304985. Date of Electronic Publication: 2024 Jun 06 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

مواضيع طبية MeSH: CD47 Antigen*/antagonists & inhibitors , CD47 Antigen*/immunology , Receptors, Immunologic*/antagonists & inhibitors , Receptors, Immunologic*/metabolism , Receptors, Immunologic*/immunology , Immunoconjugates*/pharmacology , Antigens, Differentiation*/immunology, Animals ; Humans ; Mice ; Cell Line, Tumor ; Female ; Trastuzumab/pharmacology ; Topoisomerase I Inhibitors/pharmacology ; Immunotherapy/methods ; Mice, Inbred BALB C

المؤلفون: Iemitsu K; Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; Meiji University International Institute for Bio-Resource Research, Kawasaki, Kanagawa, Japan., Sakai R; Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; Meiji University International Institute for Bio-Resource Research, Kawasaki, Kanagawa, Japan., Maeda A; Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan., Gadomska K; Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan., Kogata S; Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan., Yasufuku D; Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan., Matsui J; Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan., Masahata K; Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan., Kamiyama M; Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan., Eguchi H; Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan., Matsumura S; Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan., Kakuta Y; Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan., Nagashima H; Meiji University International Institute for Bio-Resource Research, Kawasaki, Kanagawa, Japan., Okuyama H; Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan., Miyagawa S; Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; Meiji University International Institute for Bio-Resource Research, Kawasaki, Kanagawa, Japan. Electronic address: miyagawa@pedsurg.med.osaka-u.ac.jp.

المصدر: Transplant immunology [Transpl Immunol] 2024 Jun; Vol. 84, pp. 102020. Date of Electronic Publication: 2024 Mar 06.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9309923 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-5492 (Electronic) Linking ISSN: 09663274 NLM ISO Abbreviation: Transpl Immunol Subsets: MEDLINE

مواضيع طبية MeSH: CD47 Antigen*/metabolism , CD47 Antigen*/immunology , Neutrophils*/immunology , Neutrophils*/metabolism , Graft Rejection*/immunology , Receptors, Immunologic*/metabolism , Antigens, Differentiation*/metabolism , Antigens, Differentiation*/immunology, Humans ; Animals ; Swine ; HL-60 Cells ; Coculture Techniques ; Transplantation, Heterologous ; Endothelial Cells/immunology ; Endothelial Cells/metabolism ; Reactive Oxygen Species/metabolism

المؤلفون: Yang HW; Department of Biomedical Engineering, National Cheng Kung University, Tainan City, Taiwan.; Medical Device Innovation Center, National Cheng Kung University, Tainan City, Taiwan., Ju SP; Department of Mechanical and Electro-Mechanical Engineering, National Sun Yat-sen University, Kaohsiung, Taiwan.; Department of Medicinal and Applied Chemistry, Kaohsiung Medical University, Kaohsiung, Taiwan., Hsieh YT; Department of Mechanical and Electro-Mechanical Engineering, National Sun Yat-sen University, Kaohsiung, Taiwan., Yang YC; Department of Mechanical and Electro-Mechanical Engineering, National Sun Yat-sen University, Kaohsiung, Taiwan.

المصدر: Journal of biomolecular structure & dynamics [J Biomol Struct Dyn] 2024 May; Vol. 42 (8), pp. 3969-3982. Date of Electronic Publication: 2023 Jun 01.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 8404176 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-0254 (Electronic) Linking ISSN: 07391102 NLM ISO Abbreviation: J Biomol Struct Dyn Subsets: MEDLINE

مواضيع طبية MeSH: Molecular Dynamics Simulation* , CD47 Antigen*/chemistry , CD47 Antigen*/metabolism , Aptamers, Nucleotide*/chemistry , Protein Binding* , Antigens, Differentiation*, Humans ; DNA, Single-Stranded/chemistry ; Receptors, Immunologic/chemistry ; Receptors, Immunologic/metabolism ; Thermodynamics

المؤلفون: Tang XX; Department of Anatomy and Cell Biology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA., Shimada H; Departments of Pathology and Pediatrics, School of Medicine, Stanford University, Stanford, CA 94305, USA., Ikegaki N; Department of Anatomy and Cell Biology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.

المصدر: Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Jun 01; Vol. 31 (6), pp. 3212-3226. Date of Electronic Publication: 2024 Jun 01.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE

مواضيع طبية MeSH: CD47 Antigen*/metabolism , Neuroblastoma* , Receptors, Immunologic*/metabolism , Antigens, Differentiation*, Humans ; Macrophages/metabolism

المؤلفون: Yu J; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China., Li S; ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd., Shanghai 201203, China., Chen D; ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd., Shanghai 201203, China., Liu D; ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd., Shanghai 201203, China., Guo H; ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd., Shanghai 201203, China., Yang C; ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd., Shanghai 201203, China., Zhang W; ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd., Shanghai 201203, China., Zhang L; ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd., Shanghai 201203, China., Zhao G; ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd., Shanghai 201203, China., Tu X; ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd., Shanghai 201203, China., Peng L; ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd., Shanghai 201203, China., Liu S; ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd., Shanghai 201203, China., Bai X; ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd., Shanghai 201203, China., Song Y; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China., Jiang Z; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China., Zhang R; ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd., Shanghai 201203, China., Tian W; ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd., Shanghai 201203, China.

المصدر: Molecules (Basel, Switzerland) [Molecules] 2022 Aug 30; Vol. 27 (17). Date of Electronic Publication: 2022 Aug 30.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE

مواضيع طبية MeSH: Amino Acids*/chemistry , Antigens, Differentiation*/chemistry , CD47 Antigen*/chemistry , Receptors, Immunologic*/chemistry, Humans ; Phagocytosis ; Protein Binding ; Recombinant Fusion Proteins/chemistry

المؤلفون: Gondois-Rey F; Immunity and Cancer Team, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille University UM105, Marseille, France., Miller T; Integrated Chemical and Structural Biology Team, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille University UM105, Marseille, France., Laletin V; Immunity and Cancer Team, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille University UM105, Marseille, France., Morelli X; Integrated Chemical and Structural Biology Team, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille University UM105, Marseille, France., Collette Y; Integrated Chemical and Structural Biology Team, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille University UM105, Marseille, France., Nunès J; Immunity and Cancer Team, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille University UM105, Marseille, France., Olive D; Immunity and Cancer Team, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille University UM105, Marseille, France.

المصدر: Frontiers in immunology [Front Immunol] 2022 Jun 20; Vol. 13, pp. 899068. Date of Electronic Publication: 2022 Jun 20 (Print Publication: 2022).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Antigens, Differentiation*/immunology , CD47 Antigen*/immunology , NADPH Oxidases*/immunology , NADPH Oxidases*/metabolism , Neoplasms*/immunology , Neoplasms*/therapy , Receptors, Immunologic*/immunology , T-Lymphocytes*/immunology , Trogocytosis*/immunology, Antibodies, Monoclonal/pharmacology ; Antibody-Dependent Cell Cytotoxicity ; Enzyme Activation ; Humans ; Lymphocyte Count

المؤلفون: Narla RK; Bristol Myers Squibb, 10300 Campus Point Drive, Suite 100, San Diego, CA, 92121, USA. rama.narla@bms.com., Modi H; Bristol Myers Squibb, 10300 Campus Point Drive, Suite 100, San Diego, CA, 92121, USA., Bauer D; Bristol Myers Squibb, 10300 Campus Point Drive, Suite 100, San Diego, CA, 92121, USA., Abbasian M; Bristol Myers Squibb, 10300 Campus Point Drive, Suite 100, San Diego, CA, 92121, USA., Leisten J; Bristol Myers Squibb, 10300 Campus Point Drive, Suite 100, San Diego, CA, 92121, USA., Piccotti JR; Bristol Myers Squibb, 10300 Campus Point Drive, Suite 100, San Diego, CA, 92121, USA., Kopytek S; Bristol Myers Squibb, 10300 Campus Point Drive, Suite 100, San Diego, CA, 92121, USA., Eckelman BP; Inhibrx, San Diego, CA, USA., Deveraux Q; Inhibrx, San Diego, CA, USA., Timmer J; Inhibrx, San Diego, CA, USA., Zhu D; Bristol Myers Squibb, 10300 Campus Point Drive, Suite 100, San Diego, CA, 92121, USA., Wong L; Bristol Myers Squibb, 10300 Campus Point Drive, Suite 100, San Diego, CA, 92121, USA., Escoubet L; Bristol Myers Squibb, 10300 Campus Point Drive, Suite 100, San Diego, CA, 92121, USA., Raymon HK; Bristol Myers Squibb, 10300 Campus Point Drive, Suite 100, San Diego, CA, 92121, USA.; Artiva Biotherapeutics, San Diego, CA, USA., Hariharan K; Bristol Myers Squibb, 10300 Campus Point Drive, Suite 100, San Diego, CA, 92121, USA.

المصدر: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2022 Feb; Vol. 71 (2), pp. 473-489. Date of Electronic Publication: 2021 Jul 10.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal/*pharmacology , Antigens, Differentiation/*immunology , CD47 Antigen/*immunology , Immunoglobulin Fc Fragments/*immunology , Leukemia, Promyelocytic, Acute/*drug therapy , Macrophages/*immunology , Receptors, Immunologic/*immunology, Animals ; Antibodies, Monoclonal/immunology ; Antigens, Differentiation/metabolism ; Antineoplastic Agents, Immunological/immunology ; Antineoplastic Agents, Immunological/pharmacology ; Apoptosis ; CD47 Antigen/metabolism ; Cell Differentiation ; Cell Proliferation ; Female ; Humans ; Leukemia, Promyelocytic, Acute/immunology ; Leukemia, Promyelocytic, Acute/metabolism ; Leukemia, Promyelocytic, Acute/pathology ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Phagocytosis ; Prognosis ; Receptors, Immunologic/metabolism ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays

المؤلفون: Dehmani S; OSE Immunotherapeutics, Nantes, France.; Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France., Nerrière-Daguin V; Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France., Néel M; Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France., Elain-Duret N; Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France., Heslan JM; Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France., Belarif L; OSE Immunotherapeutics, Nantes, France., Mary C; OSE Immunotherapeutics, Nantes, France., Thepenier V; OSE Immunotherapeutics, Nantes, France., Biteau K; OSE Immunotherapeutics, Nantes, France., Poirier N; OSE Immunotherapeutics, Nantes, France., Blancho G; Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France., Haspot F; Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France.

المصدر: Frontiers in immunology [Front Immunol] 2021 Dec 01; Vol. 12, pp. 732530. Date of Electronic Publication: 2021 Dec 01 (Print Publication: 2021).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Antigens, Differentiation/*metabolism , CD47 Antigen/*metabolism , Graft vs Host Disease/*immunology , Lymphocyte Activation/*drug effects , Muromonab-CD3/*administration & dosage , Receptors, Immunologic/*metabolism , Signal Transduction/*drug effects , T-Lymphocytes/*immunology, Animals ; Antigens, Differentiation/genetics ; Antigens, Differentiation/immunology ; Blood Donors ; CD47 Antigen/genetics ; Disease Models, Animal ; Female ; Gene Knock-In Techniques ; Gene Knockout Techniques ; Healthy Volunteers ; Heterografts ; Humans ; Jurkat Cells ; Lymphocyte Activation/genetics ; Male ; Mice ; Muromonab-CD3/immunology ; Receptors, Immunologic/genetics ; Receptors, Immunologic/immunology ; Signal Transduction/genetics

المؤلفون: Wang Z; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)., Hu N; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)., Li X; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)., Wang H; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)., Ren C; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)., Qiao C; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)., Chen G; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)., Wang J; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)., Zhou L; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)., Wu J; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)., Zhang D; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)., Feng J; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)., Shen B; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.)., Peng H; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.) luoll@bmi.ac.cn p_h2002@hotmail.com., Luo L; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China (Z.W., N.H., X.L., C.Q., G.C., J.W., L.Z., J.W., D.Z., J.F., B.S., L.L.); School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China (H.W., H.P.); Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin, China (H.P.); Department of Hematology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China (H.W.); and Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China (C.R.) luoll@bmi.ac.cn p_h2002@hotmail.com.

المصدر: Molecular pharmacology [Mol Pharmacol] 2021 Sep; Vol. 100 (3), pp. 193-202. Date of Electronic Publication: 2021 Jul 27.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 0035623 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0111 (Electronic) Linking ISSN: 0026895X NLM ISO Abbreviation: Mol Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Antigens, Differentiation/*genetics , Antigens, Differentiation/*immunology , CD47 Antigen/*immunology , Receptors, Immunologic/*genetics , Receptors, Immunologic/*immunology, Animals ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antigens, Differentiation/adverse effects ; Antigens, Differentiation/chemistry ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Burkitt Lymphoma/drug therapy ; Burkitt Lymphoma/immunology ; Burkitt Lymphoma/pathology ; CD47 Antigen/chemistry ; CHO Cells ; Cell Line ; Cricetulus ; Drug Design ; Epitopes/chemistry ; Epitopes/genetics ; Epitopes/immunology ; Hemagglutination/drug effects ; Immunotherapy ; Mice, SCID ; Models, Molecular ; Phagocytosis/drug effects ; Phagocytosis/immunology ; Receptors, Immunologic/chemistry ; Recombinant Fusion Proteins/adverse effects ; Recombinant Fusion Proteins/chemistry ; Recombinant Fusion Proteins/genetics ; Recombinant Fusion Proteins/immunology ; Rituximab/therapeutic use ; Tumor Burden/drug effects ; Xenograft Model Antitumor Assays ; Mice

المؤلفون: Bouwstra R; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., van Meerten T; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Bremer E; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

المصدر: Clinical and translational medicine [Clin Transl Med] 2022 Aug; Vol. 12 (8), pp. e943.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 101597971 Publication Model: Print Cited Medium: Internet ISSN: 2001-1326 (Electronic) Linking ISSN: 20011326 NLM ISO Abbreviation: Clin Transl Med Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Bispecific*/pharmacology , Antibodies, Bispecific*/therapeutic use , Neoplasms*/drug therapy, Antigens, Differentiation/*metabolism , Receptors, Immunologic/*metabolism, Antigens, Differentiation/pharmacology ; CD47 Antigen/metabolism ; CD47 Antigen/therapeutic use ; Humans ; Immunologic Factors/pharmacology ; Immunologic Factors/therapeutic use ; Immunotherapy ; Phagocytosis ; Receptors, Immunologic/therapeutic use